Abstract
Our report presents a case of a patient treated with ALK inhibitor crizotinib in the second line according to the EML4-ALK proven translocation. Tumor stopped a response to this therapy after a few months, probably due to so called ALK-dependent resistance, because ALK inhibitor of the second generation, ceritinib, re-induced partial remission of the disease and improve the patient's condition.
Detection of the reason of resistance to initial treatment and eventual rebiopsy among patients may permit to get an adequate specific treatment other lines and thereby maintain tumor control for considerably longer periods. Thank this fact, it has already been possible to call lung cancer almost as chronic diseases, at least in some patients.